tbuckley/cabot-search huggingface dataset:
Palliative care and end-of-life care in metastatic pancreatic cancer.
Authors: Jenny O'Brien, Brenton S. Halsey, Meghan Connors, Giuliana Berardi, Vruksha Upadhyay, Jessica R Bauman, Efrat Dotan
Journal: Journal of Clinical Oncology (2022)

544 Background: Patients with metastatic pancreatic cancer (mPC) have a 5-year survival of 2.7%. Studies have shown that patients with mPC receive aggressive end of life (EOL) care which has been associated with worse quality of life for patients and high use of resources when they are least likely to benefit patients. Methods: A retrospective database of patients with mPC treated at Fox Chase Cancer Center between 2010 and 2019 was analyzed for utilization of palliative care and EOL care. Statistical analysis was performed using one-sample Z tests calculated in Excel. Results: We identified 610 patients with mPC, of whom 39% received palliative care, 56% were referred to hospice, and 91.8% are deceased. The average time from mPC diagnosis to palliative care consult was 232 days, the average time from palliative care consult to death was 121 days. Patients who received palliative care were less likely to receive chemotherapy within 14 days of death (7.7% vs 13.3%, p =0.05), more likely to have a DNR code status (83.3% vs 44.5%, p &lt; 0.0001), and more likely to be referred to hospice (83.9% vs 35.9%, p &lt; 0.0001). The average length of time on hospice was 24 days with no difference between those who received palliative care and those who did not. Patients who were referred to hospice were also less likely to receive chemotherapy within 14 days of death (6.7% vs 19.8%, p &lt; 0.0001). Conclusions: Patients with mPC who had a palliative care team involved in their care were significantly less likely to receive aggressive EOL care.
DR. EMIN PASHA
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Constipation in Adults and Children; with Special Reference to Habitual Constipation in Its Most Successful Treatment by the Mechanical Methods.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, April 10 to May 10, 1964
Journal: JNCI Journal of the National Cancer Institute (1964)

Manuscripts Approved for JNCI, April 10 to May 10, 1964 JNCI: Journal of the National Cancer Institute, Volume 32, Issue 6, June 1964, Pages 1374–1375, https://doi.org/10.1093/jnci/32.6.1374 Published: 01 June 1964
Core decompression in avascular necrosis of the hip in sickle‐cell disease
Authors: Lori A. Styles, Elliott P. Vichinsky
Journal: American Journal of Hematology (1996)

Sickle-cell disease (SCD) is the most common cause of avascular necrosis (AVN) of the hip in childhood. It results in significant physical impairment and chronic pain, and often progresses to require hip replacement. Conservative therapy is ineffective. We evaluated whether core decompression can arrest progression of AVN. We performed 13 coring procedures in 10 patients with SCD and AVN. Patients ranged from age 9–21 years at diagnosis (mean, median age, 15 years); five hips were stage I, six hips were stage II, and two hips were stage III. Mean follow-up on these patients was 3.7 years. Efficacy of the procedure was evaluated by clinical improvement in pain, radiographic progression, and need for further surgery. All 5 stage I patients had substantial improvement in pain, and only one showed X-ray progression. Five of the 6 (83%) stage II patients had improvement in pain, and 2 patients progressed on X-ray. Both stage III patients progressed on X-ray, but one was clinically improved. None of the 10 patients has required further surgery. Our results demonstrate that in early AVN, core decompression was beneficial for almost all patients, even with progression on X-ray. Core decompression should be considered in the management of SCD patients with early AVN. © 1996 Wiley-Liss, Inc.
Correction: Remdesivir for Adults With COVID-19
Authors: Anjum S. Kaka, MD, Roderick MacDonald, MS, Nancy Greer, PhD, Kathryn Vela, MLIS, Wei Duan-Porter, MD, PhD
Journal: Annals of Internal Medicine (2021)

Corrections16 March 2021Correction: Remdesivir for Adults With COVID-19FREEThis correction concerns the following article:ReviewsMay 2021Major Update: Remdesivir for Adults With COVID-19FREEAnjum S. Kaka, MD, Roderick MacDonald, MS, Nancy Greer, PhD, Kathryn Vela, MLIS, Wei Duan-Porter, MD, PhDAnjum S. Kaka, MDMinneapolis VA Health Care System and University of Minnesota School of Medicine, Minneapolis, Minnesota (A.S.K., W.D., T.J.W.), Roderick MacDonald, MSMinneapolis VA Health Care System, Minneapolis, Minnesota (R.M., N.G.), Nancy Greer, PhDMinneapolis VA Health Care System, Minneapolis, Minnesota (R.M., N.G.), Kathryn Vela, MLISVA Portland Health Care System, Portland, Oregon (K.V., A.O.)., Wei Duan-Porter, MD, PhDMinneapolis VA Health Care System and University of Minnesota School of Medicine, Minneapolis, Minnesota (A.S.K., W.D., T.J.W.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0130 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the article by Kaka and colleagues (1), the description of the magnitude of the mortality reduction with remdesivir for the subgroup of patients receiving supplemental oxygen but not needing ventilation was changed from "moderate decrease" to "small decrease." Although the risk ratio, absolute risk difference (ARD), and associated 95% CIs were correct, the authors' interpretation of the magnitude was wrong; per their thresholds for the magnitude of effect for mortality, an ARD of 1% to 2.9% indicates a small effect, and an ARD of 3% to 4.9% indicates a moderate effect.The online version has been corrected.Reference1. Kaka AS, MacDonald R, Greer N, et al. Major update: remdesivir for adults with COVID-19. A living systematic review and meta-analysis for the American College of Physicians practice points. Ann Intern Med. 9 February 2021 [Epub ahead of print]. [PMID: 33560863] doi:10.7326/M20-8148 LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationThis article was published at Annals.org on 16 March 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMajor Update: Remdesivir for Adults With COVID-19 Anjum S. Kaka , Roderick MacDonald , Nancy Greer , Kathryn Vela , Wei Duan-Porter , Adam Obley , and Timothy J. Wilt Metrics May 2021Volume 174, Issue 5Page: 736 ePublished: 16 March 2021 Issue Published: May 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The gendered dimensions of COVID-19
Authors: None The Lancet
Journal: The Lancet (2020)

SARS-CoV-2 does not discriminate, but without careful consideration, the global response to the COVID-19 pandemic might. Demographic data from small studies are already informing political decisions and clinical research strategies. Women and men are affected by COVID-19, but biology and gender norms are shaping the disease burden. The success of the global response—the ability of both women and men to survive and recover from the pandemic's effects—will depend on the quality of evidence informing the response and the extent to which data represent sex and gender differences.
Selected Abstracts
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laparoscopic Cholecystectomy
Authors: Bruce M. Wolfe
Journal: JAMA (1991)

Several remarkable developments have occurred over the last 2 years in the management of symptomatic gallstones. A fundamentally different technique for the conduct of cholecystectomy was developed, described, and popularized by surgeons in both France and the United States.<sup>1,2</sup>The technique is described briefly by Miller-Catchpole<sup>3</sup>in this issue ofThe Journaland involves the use of a laparoscope and instrument insertion through trocars, thereby avoiding the traditional incision. Advantages attributed to laparoscopic cholecystectomy compared with the traditional or open cholecystectomy include diminished postoperative pain, shorter hospitalization and associated cost, more rapid recovery and return to full activity, and a superior cosmetic result. Initial reports on the laparoscopic procedure were followed by an unprecedented (at least for biliary tract surgeons) rush by surgeons to learn the new technique, advertisements and/or promotions by both the manufacturers of the required equipment and health care providers, and consumer demand for the
The role of 15 lipoxygenase 1 in asthma comes into focus
Authors: Joshua A. Boyce
Journal: Journal of Clinical Investigation (2022)

IL-4- and IL-13-driven epithelial cell expression of 15 lipoxygenase 1 (15LO1) is a consistent feature of eosinophil-dominated asthma known as type 2-high (T2-high) asthma. The abundant soluble products of arachidonic acid (AA) metabolized by 15LO1 reflect a high level of enzymatic activity in asthma and chronic rhinosinusitis. However, the precise role of 15LO1 and its products in disease pathogenesis remains enigmatic. In this issue of the JCI, Nagasaki and colleagues demonstrate a role for 15LO1 in controlling redox balance and epithelial homeostasis in T2-high asthma by metabolizing AA that is esterified to membrane phospholipids. The findings may pave the way toward the development of 15LO1 inhibitors as asthma treatments.
Poster Discussions
Authors: P. Pelosi, M. Croci, D. Chiumello, A. Pedoto, L. Gattinoni, S. Nunes, P. Valta, J. Takala, R. Fretschner, T. Winkler, R. Fretschner, Th. P. Laubscher, J. X. Brunner, M. Imhoff, J. H. Lehner, D. Löhlein, G. Foti, ME. Sparacino, M. Cereda, L. De Marchi, N. Patroniti, D. Weismann, A. Pesenti, G. Foti, A. De Salve, L. Zappa, D. Stefania, ME. Sparacino, R. Zavaglio, A. Pesenti, L. Zappa, A. Sordi, H. Reissmann, O. Katzenstein, A. Prause, B. Fuellekrug, W. Pothmann, K. Crowley, M. Geoghegan, F. Colreavy, D. McMahon, M. Doyle, G. Conti, M. Rocco, S. Tarquini, L. Ruscio, M. Gionfrida, A. Lappa, M. Antonelli, T. Kubota, K. Murata
Journal: Intensive Care Medicine (1996)
Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study
Authors: Renata Abrahão, Ruth H Keogh, Daphne Y Lichtensztajn, Rafael Marcos-Gragera, Bruno C. Medeiros, MIchel P Coleman, Raul C. Ribeiro, Theresa HM Keegan
Journal: Blood (2015)
Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta‐analysis
Authors: José Laerte Boechat, Diana Silva, Bernardo Sousa‐Pinto, Luís Delgado
Journal: Allergy (2022)

All authors declare that they have no conflicts of interest to disclose. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Numbers, numerosities, and new directions
Authors: Sam Clarke, Jacob Beck
Journal: Behavioral and Brain Sciences (2021)

Abstract In our target article, we argued that the number sense represents natural and rational numbers. Here, we respond to the 26 commentaries we received, highlighting new directions for empirical and theoretical research. We discuss two background assumptions, arguments against the number sense, whether the approximate number system (ANS) represents numbers or numerosities, and why the ANS represents rational (but not irrational) numbers.
The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma.
Authors: Weili Xu, Youhua Jiang, Changchun Wang, Jie Wu, Jianqiang Li, Yuqian Hu, Weishan Lu, Dijian Shen, Yinjie Wang, Qixun Chen
Journal: Journal of Clinical Oncology (2022)

278 Background: To explore the efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC) by an open label, single-arm, phase 2 clinical trial (ClinicalTrials.gov, Identifier number: NCT04506138). Methods: The eligible patients were arranged to receive 2 cycles of camrelizumab (200mg, day 1) combined with carboplatin (AUC = 5, day 1) and albumin paclitaxel (100 mg/m 2 , day 1, 8). All treatments were given intravenously in 3-week cycle. Patients underwent surgery within 4-6 weeks after the completion of neoadjuvant treatment. The primary endpoint was pathologic complete response (pCR), and secondary endpoints were major pathological response (MPR), safety and feasibility. The quality of life (QoL) was assessed by the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) scale and EQ-5D-3L scale. Results: A total of 46 patients were recruited, among whom the clinical stage II, III, and IVa at baseline were 11 (23.9%), 33 (71.7%), and 2 (4.3%), respectively. Forty-five patients completed 2 cycles of neoadjuvant treatment. One patient received 1 cycle of neoadjuvant treatment and then lost to be followed up. Eight patients did not receive surgery. Except 1 patient accept exploratory surgery, 37 patients (37/46, 80.4%) achieved R0 resection. Eight patients (8/37, 21.6%) had pCR in both primary tumors and lymph nodes. MPR of primary tumors and lymph nodes was observed in 18 patients (18/37, 48.6%). During neoadjuvant treatment period, all 46 patients presented with treatment-related AEs (TRAEs) of any grade. Seven patients (7/46,15.2%) experienced grade ≥ 3 TRAEs. One patient suffered grade 5 immune-associated pneumonia. The most common TRAEs were anemia (32/46, 70.0%), followed by thrombocytopenia (15, 32.6%), leukopenia (14, 30.4%), neutropenia (13, 28.3%), rash (12, 26.1%), reactive cutaneous capillary endothelial proliferation (RCCEP) (7, 15.2%). The median interval between the first cycle of neoadjuvant treatment and surgery was 64 days (range, 56-77 days). Symptom scores in FACT-E scale were improved by neoadjuvant treatment (t = -2.60, P = 0.01). PD-L1 CPS (&lt; 10 vs ≥ 10), PD-L1 TPS (&lt; 1% vs ≥ 1%) and TMB (split according to top 20% of TMB value) had no effect on the pCR rate and MPR rate. Conclusions: Neoadjuvant camrelizumab combined with chemotherapy achieved a promising pathologic response, which was effective and safe. Meanwhile, neoadjuvant treatment improved QoL of patients. Some larger multi-center trials are undergoing for further confirmation of efficacy and safety. Clinical trial information: NCT04506138.
Commentary
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Emerging vaccine nanotechnology: From defense against infection to sniping cancer
Authors: Chan Feng, Yongjiang Li, Bijan Emiliano Ferdows, Dylan Neal Patel, Jiang Ouyang, Zhongmin Tang, Na Kong, Enguo Chen, Wei Tao
Journal: Acta Pharmaceutica Sinica B (2022)

Looking retrospectively at the development of humanity, vaccination is an unprecedented medical landmark that saves lives by harnessing the human immune system. During the ongoing coronavirus disease 2019 (COVID-19) pandemic, vaccination is still the most effective defense modality. The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights promising future of nanotechnology in vaccine development. Compared with conventional vaccines, nanovaccines are supposed to have advantages in lymph node accumulation, antigen assembly, and antigen presentation; they also have, unique pathogen biomimicry properties because of well-organized combination of multiple immune factors. Beyond infectious diseases, vaccine nanotechnology also exhibits considerable potential for cancer treatment. The ultimate goal of cancer vaccines is to fully mobilize the potency of the immune system as a living therapeutic to recognize tumor antigens and eliminate tumor cells, and nanotechnologies have the requisite properties to realize this goal. In this review, we summarize the recent advances in vaccine nanotechnology from infectious disease prevention to cancer immunotherapy and highlight the different types of materials, mechanisms, administration methods, as well as future perspectives.
Abstracts
Journal: Annals of the Rheumatic Diseases (1949)

The authors report 6 cases of rheumatic pneumonitis with post-mortem findings in 5.They describe the Masson body or granuloma, focal fibrinoid necrosis and alveolitis, arteriolitis, and septal-cell proliferation.No therapeutic measures seemed to be of value.They emphasize that rheumatic pneumonitis is of grave prognostic significance.
A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.
Authors: Anup Kasi, Jose Luis Iglesias
Journal: Journal of Clinical Oncology (2022)

TPS620 Background: GP-2250 is a metabolic enzyme inhibitor that selectively induces oxidative stress, mitochondrial dysfunction, and apoptosis in cancer cells by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and limiting aerobic glycolysis, an essential process for energy production in cancer cells. In vitro, increasing concentrations of GP-2250 induced proportional dose-response effects in 5 different pancreatic cancer cell lines (Buchholtz BMC Cancer 2017). Patient-derived pancreatic xenograft studies in mice demonstrated tumor growth inhibition with GP-2250 monotherapy (Braumann J Clin Oncol 2020). In combination with gemcitabine, a synergistic effect was shown with greater inhibition of pancreatic tumor growth than with either gemcitabine or GP-2250 alone. These findings support the assessment of the therapeutic potential of GP-2250 in combination with gemcitabine in patients with pancreatic cancer. Methods: This open-label phase 1/2 trial will evaluate the safety and tolerability of escalating doses of GP-2250 and the preliminary efficacy of GP-2250 in combination with gemcitabine in patients with advanced unresectable or metastatic pancreatic adenocarcinoma who have progressed on prior treatment with FOLFIRINOX chemotherapy. In phase 1, Bayesian Optimal Interval design will be used for GP-2250 dose escalation. The dose-limiting toxicity (DLT)–assessment period will be 5 weeks at each dose level (starting dose 250 mg once weekly intravenously), consisting of a 1-week run-in period with GP-2250 monotherapy, followed by a full cycle of GP-2250 plus standard dose and schedule of gemcitabine. Single patient cohorts (100% dose escalation between cohorts) will be enrolled until the occurrence of the first DLT (or cohort 4 if no DLTs occur in cohorts 1−3), after which, cohorts will be expanded to 3 patients with 35%−45% dose escalations between cohorts. Patients will receive treatment until disease progression or development of unacceptable toxicity. Primary study endpoints include safety and tolerability of GP-2250, tumor response (RECIST 1.1), disease control rate (complete response, partial response, stable disease), and duration of response. Pharmacokinetics, incidence and severity of laboratory abnormalities and treatment-emergent adverse events, progression-free survival, and overall survival will also be assessed. As of September 2021, 19 patients have been enrolled. Following completion of the phase 1/2 trial, a phase 3 first-line maintenance study will be initiated. This study is funded by Geistlich Pharma AG. Clinical trial information: NCT03854110. Clinical trial information: NCT03854110.